Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically Ill and Immunocompromised Patients

MLA

Richard Fritz, et al. “Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically Ill and Immunocompromised Patients.” Clinical and Vaccine Immunology, vol. 21, June 2014, pp. 867–76. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ea98f9bcd536664191f7afd66a4fa14d&authtype=sso&custid=ns315887.

APA

Richard Fritz, Wolfgang Herr, Thomas Dvorak, P. Noel Barrett, Christoph Stephan, Markus Zeitlinger, Eva Distler, Robert Sauermann, Hartmut J. Ehrlich, Gerald Aichinger, Brian A. Crowe, Alexander Geisberger, Daniel Portsmouth, Eva Wagner, & Maikel V. W. van der Velden. (2014). Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically Ill and Immunocompromised Patients. Clinical and Vaccine Immunology, 21, 867–876.

Chicago

Richard Fritz, Wolfgang Herr, Thomas Dvorak, P. Noel Barrett, Christoph Stephan, Markus Zeitlinger, Eva Distler, et al. 2014. “Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically Ill and Immunocompromised Patients.” Clinical and Vaccine Immunology 21 (June): 867–76. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ea98f9bcd536664191f7afd66a4fa14d&authtype=sso&custid=ns315887.